Memantine prevents quinolinic acid-induced hippocampal damage

Area of Science:

• Neuroscience
• Pharmacology
• Neuroprotection

Background:

• Glutamate receptor agonists like quinolinic acid can cause significant brain damage.
• The hippocampal formation is particularly susceptible to excitotoxic injury.
• Memantine is a drug used for spasticity, extrapyramidal disorders, and dementia.

Purpose of the Study:

• To investigate the neuroprotective effects of memantine against quinolinic acid-induced brain damage.
• To determine the efficacy of chronic memantine administration in protecting hippocampal neurons.

Main Methods:

• Animals were pretreated with memantine in their food for 10 days prior to intracerebroventricular (i.c.v.) injection of quinolinic acid.
• Additional intraperitoneal (i.p.) administration of memantine was tested.
• Protection of hippocampal neurons was assessed.

Main Results:

• Chronic memantine pretreatment reliably protected hippocampal neurons from quinolinic acid-induced damage.
• Simultaneous or delayed i.p. administration of memantine did not significantly enhance the protective effects of the dietary memantine.
• The study focused on the vulnerability of the hippocampal formation to excitotoxicity.

Conclusions:

• Memantine demonstrates significant neuroprotective potential against excitotoxic brain damage mediated by glutamate.
• Chronic administration appears crucial for memantine's protective efficacy.
• Findings suggest memantine may be beneficial for treating neurological disorders involving glutamate excitotoxicity.